26 Aug 2016
The College of Clinician Scientists is pleased to collaborate with NMRC, Quintiles and the AHCC Trials Group in organising the INVESTIGATOR-INITIATED TRIALS WORKSHOP. COMPLIMENTARY registration for Fellows of the Academy and Members of the AHCC Trials Group.
At the Investigator-Initiated Trials Workshop, participants can learn various strategies to manage trials and learn from experts on useful tips to develop budgets, identifying opportunities and potential pitfalls. Industry will also be invited to share their perspectives on the kinds of proposals that interest them, who and how to approach industry, the existing review processes and the benefits of various partnerships with industry to address current research needs.
Programme Details:
Date: 26 August 2016
Time: 2.00 pmto 5.00 pm
Venue: Auditorium, Level 8, National Dental Centre Singapore, Second Hospital Avenue, Singpaore 168938
Speakers' Information
Prof Pierce K.H Chow
Professor, DukeNUS Medical School, Singapore
Senior Consultant Surgeon
National Cancer Center Singapore and Singapore General Hospital
Pierce Chow is Co-Director (Surgical) of the Comprehensive Liver Cancer Clinic at the National Cancer Centre Singapore and Senior Consultant Surgeon in HPB and Transplant Surgery at the Singapore General Hospital. He is concurrently Professor and Course Director at the DukeNUS Medical School Singapore, NMRC Senior-Clinician Scientist and Adjunct Faculty at the Genome Institute of Singapore.
Professor Chow was the Chapter of Surgeon’s Gold Medallist at the conjoint Royal College of Surgeons of Edinburgh/M.Med examination in 1994 and was recipient of the Young Surgeon’s Award of the Academy of Medicine for his research on liver regeneration in 1995.
Professor Chow completed a fellowship in Liver Transplantation in Australia and leads multi-disciplinary translational research on the genomic heterogeneity of hepatocellular carcinoma. In 1998 He co-founded the Asia-Pacific Hepatocellular Carcinoma Trials Group and has been the protocol chair of 5 multi-national prospective clinical trials. In 2012 the National Medical Research Council Singapore conferred upon him the National Outstanding Clinician-Scientist Award for his research on Liver Cancer.
Prof Chow was awarded the NMRC Translational-Clinical Research Grant for the Flagship Program in Liver Cancer in 2016. He is the inaugural President of the College of Clinician-Scientist.
A/Professor Teoh Yee Leong
Chief Executive Officer, SCRI
Associate Professor, Saw Swee Hock School of Public Health, National University
of Singapore
A/Prof Teoh Yee Leong is the Chief Executive Officer at SCRI. He is a Public Health Physician with more than 20 years experience in public health and clinical research. SCRI is currently supporting many oncology, cardiology, ophthalmology and infectious disease clinical trials in Asia.
Prior to his current role, he was Vice-President and General Manager for Emergent Biosolutions Asia Pacific from 2010 to 2013 where he was involved in research in flu, tuberculosis and anthrax vaccine. A/Prof Teoh has in-depth experience in the development of vaccines and immunotherapeutic products.
As Director of Clinical Research and Medical Affairs for GlaxoSmithKline (Singapore, Malaysia and Brunei) from 2000 to 2005, A/Prof Teoh conducted one of the largest Phase III vaccine clinical trials in Singapore involving more than 6,000 subjects for a Rotavirus vaccine. He was also involved in clinical trials in various other vaccines including MMRV, HPV and pandemic flu vaccine.
A/Prof Teoh’s previous clinical appointment included being physician and Head, Jurong Polyclinic, National Healthcare Group Polyclinics and Assistant Commissioner of Public Health, Ministry of the Environment, Singapore.
A/Prof Toh Han Chong
Senior Consultant and Deputy Director, NCCS
Vice-Chair, Oncology Academic Clinical Program (ACP) for Education
Dr Toh Han Chong is Senior Consultant and Deputy Director, National Cancer Centre Singapore (NCCS). He is Vice-Chair of Oncology Academic Clinical Program (ACP) for Education. He is Associate Professor at the Cancer & Stem Cell Biology Program, Duke-NUS, and adjunct Principal Investigator, Institute of Molecular and Cell Biology, A*STAR. He is former Head, Division of Medical Oncology, NCCS and past president of the Singapore Society of Oncology and past chairman of the Chapter of Medical Oncology, Singapore and currently an Examiner for the National Residents Assessment Committee for Medical Oncology. He is the chairman of the advisory board for the SingHealth Investigational Medicine Unit.
Dr Toh graduated from the University of London, UK, with an Intercalated Bachelor of Science in ‘Infection and Immunity’ from St Mary’s Hospital Medical School and qualified as a medical doctor from University of Cambridge, UK. Dr Toh obtained his Fellowship of the Royal College of Physicians in 2003. He received his medical oncology fellowship training at the Singapore General Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, USA and at the Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas, USA.
Dr Toh is a recipient of the National Clinician Scientist Award for his pioneering work in cell therapy for cancer. He conducted the first cancer vaccine and T cell therapy clinical trials in Singapore, and continues to work actively in the field of cancer immunotherapy, immunology and inflammation. He also had a strong interest in drug development for gastrointestinal cancers including colon and liver cancer. He has given many plenary lectures both regionally and internationally mainly in the field of immuno oncology. Dr Toh has published over 90 peer review journal papers to date.
A/Prof Christopher Chen
Senior Clinician-Scientist, NMRC
Associate Professor, Dept of Pharmacology, Faculty of Medicine, NUS
Director, Memory of Aging and Cognition Centre, National University Healthcare System
Dr Christopher Chen is a Senior Clinician-Scientist at the National Medical Research Council of Singapore, Associate Professor at the Department of Pharmacology, Faculty of Medicine, National University of Singapore, and Director of the Memory Aging and Cognition Centre, National University Healthcare System.
He read for the Medical and Natural Science Tripos at Fitzwilliam College, Cambridge University, graduating in Physiology & Psychology in 1982. His clinical training was at the University of Oxford from where he graduated in 1985. In 1990, he was elected the Janssen Junior Research Fellow at Worcester College, Oxford University and was a Visiting Research Fellow at the Institute of Neurology, London.
His major research and clinical interests are the neurochemistry, molecular biology and treatment of stroke and dementia. He has published over 250 peer reviewed papers and book chapters, serves on journal editorial boards and has been a member of several trial steering committees and advisory panels.
Since returning to Singapore in 1995, Dr Chen has developed comprehensive multi-disciplinary dementia programmes and collaborative research in the Asia-Pacific region and beyond through a Trials Unit focusing on stroke and dementia with extensive international collaborations.
Currently he is Chair of the International Society for Vascular Behavioural and Cognitive Disorders Executive Committee, Chair of the Vascular Cognitive Disorders Professional Interest Area, International Society to Advance Alzheimer's Research and Treatment, Secretary-General of the Asian Society Against Dementia; member of the World Stroke Organisation Board of Directors and its Finance Committee as well as the Constitutional Committee of the World Federation of Neurology.
Chris King
Oncology Head, China and South-East Asia
IMS Health Asia Pte Ltd
Chris is responsible for leading the direction of the next generation of IMS’s oncology offerings and services in the region. He is also the regions therapeutic expert for oncology related consulting engagements.
Prior to joining IMS, Chris was the Head of the European Oncology Monitor at Ipsos, directly responsible for product development, team leadership, staff management and client servicing for the firm’s European Oncology Monitor business. Chris was previously at Datamonitor’s Healthcare Consulting practice, working on various global strategic pharmaceutical and biotech consultancy projects, covering major markets as well as emerging markets. Chris’s focus in consulting was on commercial product forecast modeling, market and product assessments, and product positioning/launch strategy.
Before obtaining his MBA at London Business School in 2005, Chris was the laboratory information manager for numerous clinical research projects at the British Columbia Cancer Research Centre. In this role Chris was responsible for database design and implementation, quality control and statistics.
Dr Mark A. Bach
Vice President, Asia Pacific Medical Sciences
China Innovation Leader
Janssen Research & Development
Mark Bach is Vice President for Asia Pacific Medical Sciences and China Innovation Leader for Janssen R&D.
In January 2010, Mark joined Johnson & Johnson and as Vice President, Japan Medical Organization at Janssen (Japan), based in Tokyo. In November 2012, he became Head of Asia Pacific Medical Sciences (APMS), with responsibility for Discovery, Clinical Development, and Medical Affairs across the Asia Pacific region. In addition to his APMS role, in September 2014 he was appointed to the new role, China Innovation Leader, responsible for driving execution of the Janssen R&D strategy in China.
Mark received a Ph.D. in Immunology from the University of Chicago, an M.D. from Baylor College of Medicine, and was trained in Pediatrics at Baylor College of Medicine. He was trained in Pediatric Endocrinology at the U.S. National Institutes of Health where he also did post-doctoral research, and joined the pharmaceutical industry in 1993.
Dr Senthil Sockalingam
Vice President, Head of Medical & Therapeutic Science and Strategy Unit, Asia
Dr. Sockalingam graduated from University Malaya and has more than 10 years of experience in working in high impact positions with key compounds in Asia-Pacific and China. He has been involved in clinical development strategies with a particular focus on Asia as well as managing medical affairs activities in the region for oncology and rare disease therapeutic areas.
In addition to the clear understanding of drug development strategies in Asia, he has led advisory boards and coordinated investigator-led studies for these key compounds, and in doing so he has established an extensive personal network of experts and key opinion leaders in the area of study.
Dr. Sockalingam was also the launch medical lead for Afinitor in Southeast Asia, and the senior medical expert managing the lifecycle and development for Nexavar, Kogenate and Betaferon in Asia. In addition to that, he was involved in the clinical development strategies for several orphan drugs in the lysosome storage disease space.
Prior to joining Quintiles, he held strategic positions with companies such as Bayer Healthcare, Genzyme Sanofi and Novartis, and managed key oncology, haematology and rare disease brands in Asia, including Glivec, Afinitor, Exjade, Nexavar and Kogenate, where he led the Asian clinical development strategy, and supported registration, commercialization and competitive intelligence activities to ensure the success of these compounds.
Dr. Sockalingam earned his MBBS, Medicine and Surgery, at the University of Malaya, Malaysia, and is a member of the Australasian College of Pathologists.
A/Prof David Lye Chien Boon
Senior consultant, Institute of Infectious Diseases and Epidemiology (IIDE), Tan Tock Seng Hospital
Yong Loo Lin School of Medicine, National University of Singapore
Lee Kong Chian School of Medicine, Nanyang Technological University
Principal investigator, Singapore Infectious Disease Clinical Research Network (SCRN)
Professor Lye was a co-principal investigator in STOP-dengue translational clinical research programme (2008-2014) which focused on the control, treatment and prevention of adult dengue. Highlights from clinical research in STOP-dengue included a large retrospective cohort of adult dengue from 2005 to 2008 (“ARDENT”) and a prospective adult dengue study (PADS) from 2010 to 2012, which have provided a lot of insights into the management of adult dengue especially among the elderly. A randomised clinical trial of prophylactic platelet transfusion for adult dengue patients with thrombocytopenia (ADEPT) was completed.
As the lead for SCRN, Professor Lye is involved in randomised clinical trials to optimise antibiotic use in the era of antibiotic resistance. A-KLASS is a clinical trial of oral versus intravenous antibiotics to treat Klebsiella liver abscess. MERINO and MERINO-2 are two clinical trials studying carbapenem-sparing therapy for E coli and K pneumoniae bacteraemia with extended spectrum beta-lactamases, and gram negative bacteraemia with chromosomal AmpC producers respectively, in collaboration with Australasian Society for Infectious Diseases Clinical Research Network (ASID CRN). Funded via Late Phase Clinical Trial Grant, CAMERA-2 is a clinical trial in collaboration with ASID CRN on better ways of treating methicillin-resistant S aureus bacteraemia.
A/Prof Louis Tong
Senior Consultant
Principal Clinician Scientist
Singapore National Eye Center
Faculty of Eye-ACP in DukeNUS
Assoc Prof Tong graduated in 1993 with basic medical degree from the National University of Singapore, registered as a medical practitioner in 1994 and achieved accreditation as an ophthalmologist in November 2004. He completed in training in ophthalmology at various centers in the United Kingdom (1996-2000) and in Singapore (2000-2004). He completed a 2 year overseas cornea research fellowship at the Ocular Surface Center, Baylor College of Medicine, Houston, Texas, as part of A*STAR national science scholarship.
Assoc Prof Tong is faculty of Eye-ACP in Duke-NUS, and is currently head of research training and development, ocular surface research group and co-head of ocular inflammation and immunology research groups at the Singapore Eye Research Institute (SERI). He is involved in advisory board meetings in several pharmaceutical companies, is a subcommittee member of international dry eye workshop II, and a co-inventor in a few patents. Assoc Prof Tong has been awarded the Clinician Scientist Award from National Medical Research Council (Senior investigator category). He runs a dedicated dry eye service at the Singapore National Eye Center, focusing on dry eye. He has been site principal investigator in 15 interventional studies, including industry sponsored as well as investigator initiated trials.
Kripesh Krishnan
Associate Director
Global Data and Safety Monitoring
Clinical Data Management, Quintiles
Kripesh Krishnan is working as Associate Director, Clinical Data Management at Quintiles. He is a Pharmacist by training and have a total of 12 years of experience in health care industry. During his 10.5 year stint with Quintiles, he has worked as Data Team Lead and Project Manager on various global trials and currently managing few key Customer accounts and also supervising a team of 35 vibrant staffs. Actively participates in defining data management strategies and implementations. Responsible for the on time delivery and quality of projects. To be part of a team that is having such a positive impact on patient lives is both personally and professionally rewarding to him.
Lisa Marie Saldanha
Director & Head
Academic Research Group, Quintiles
Lisa is a Pharmacist by training with over 12 years’ experience in the clinical research industry.
Currently head of the Academic Research Group, Asia Region for Quintiles, her team supports the delivery of Investigator Initiated Trials (IIT) in the region. Formally head of Regulatory and Start-up for Quintiles in Asia, Lisa’s experience spans across both the Pharmaceutical and CRO industry, in Clinical Operations, Regulatory and Project Management, experience which she now brings to the academic research environment.
A/Prof John Whay-Kuang Chia
Senior Consultant
Division of Medical Oncology
National Cancer Center Singapore
Adjunct Associate Professor DukeNUS
Dr John Chia is currently the chief of the Gynecology Team, at the NCCS Division of Medical Oncology, and visiting consultant at KK Womens and Childrens Hospital. His major passion has been to improve outcomes for cancer patients through clinical trials – and he holds scientific research grants both locally and internationally.
Dr John Chia is a Senior Consultant at the Division of Medical Oncology, National Cancer Center Singapore, and Adjunct Associate Professor at DUKE-NUS. Upon finishing of his Oncology Boards, he completed fellowship training with Malcom Brenner in the field of “Immunotherapy for Solid Tumors” at the Centre for Cell and Gene Therapy, Baylor College of Medicine, Houston; and a second fellowship with Prof Stan Kaye at The Royal Marsden Hospital London.
Dr Chia has developed and lead many investigator initiated clinical trials – for immune-checkpoint inhibitors and small molecule inhibitors, cancer vaccines, adoptive T cells.
For programme flyer, please click link.
To register, kindly complete the registration form and send it to alicia_tan@ams.edu.sg.
If you have any queries about the workshop or registration, kindly email us at alicia_tan@ams.edu.sg.
